Celldex Therapeutics (NASDAQ:CLDX) had its price target increased by Guggenheim from $26.00 to $34.00 in a research report sent to investors on Tuesday morning, AnalystRatingsNetwork.com reports. The firm currently has a buy rating on the stock.
A number of other analysts have also recently weighed in on CLDX. Analysts at Cantor Fitzgerald raised their price target on shares of Celldex Therapeutics (NASDAQ:CLDX) to $39.00 in a research note to investors on Tuesday. They now have a buy rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Celldex Therapeutics (NASDAQ:CLDX) from $28.00 to $45.00 in a research note to investors on Monday. They now have an outperform rating on the stock. Finally, analysts at Wedbush reiterated a buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research note to investors on Tuesday, September 17th. They now have a $35.00 price target on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Celldex Therapeutics has a consensus rating of Buy and a consensus price target of $32.50.
Celldex Therapeutics (NASDAQ:CLDX) traded up 5.19% on Tuesday, hitting $35.2165. The stock had a trading volume of 949,393 shares. Celldex Therapeutics has a one year low of $5.02 and a one year high of $34.49. The stock’s 50-day moving average is $23.72 and its 200-day moving average is $16.97. The company’s market cap is $2.852 billion.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.02. The company had revenue of $0.97 million for the quarter, compared to the consensus estimate of $1.57 million. During the same quarter in the previous year, the company posted ($0.23) earnings per share. The company’s revenue for the quarter was down 51.7% on a year-over-year basis. Analysts expect that Celldex Therapeutics will post $-0.97 EPS for the current fiscal year.
Celldex Therapeutics, Inc (NASDAQ:CLDX), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.